Status:
RECRUITING
Impact of Von Willebrand Factor and Its Multimers on Angiogenesis
Lead Sponsor:
Nantes University Hospital
Conditions:
Von Willebrand Diseases
Eligibility:
All Genders
18+ years
Brief Summary
The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investiga...
Eligibility Criteria
Inclusion
- For patients:
- Patient with von Willebrand disease proven by genetic analysis of the VWF gene.
- Lack of treatment that could interfere with angiogenesis.
- Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
- For the control:
- Patient with a normal coagulation report
- Absence of abnormal hemorrhagic symptoms
- Lack of notion of angiodysplasia.
- Lack of treatment that could interfere with angiogenesis.
- Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
Exclusion
- Patient under guardianship or curatorship.
- Pregnant and lactating women.
- Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.
- Treatment which may interfere with angiogenesis.
Key Trial Info
Start Date :
February 7 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 7 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04810702
Start Date
February 7 2024
End Date
August 7 2024
Last Update
March 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nantes
Nantes, France